CD5 and B-cell chronic lymphocytic leukemia: Together, these data suggest that CD5low B cells are an important component of CLL that may be able to propagate and act as a residual disease population, with implications for understanding CLL pathogenesis, minimal residual disease, and developing anti-CD5-directed therapies.